Stealth BioTherapeutics (NASDAQ:MITO) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued to investors on Wednesday, Zacks.com reports. The firm presently has a $16.00 target price on the stock. Zacks Investment Research‘s target price suggests a potential upside of 13.96% from the stock’s previous close.
According to Zacks, “Stealth BioTherapeutics Corp is a biopharmaceutical company. It is engaged in developing therapies to treat the mitochondrial dysfunction associated with genetic mitochondrial diseases and many common age-related diseases. The company’s product pipeline includes Elamipretide, SBT-20 and SBT-272 which are in clinical stage. Stealth BioTherapeutics Corp is based in Newton, Massachusetts. “
A number of other research firms also recently issued reports on MITO. Jefferies Financial Group started coverage on shares of Stealth BioTherapeutics in a report on Tuesday, March 12th. They set a “hold” rating and a $16.00 price objective for the company. Nomura started coverage on shares of Stealth BioTherapeutics in a report on Tuesday, March 12th. They set a “buy” rating and a $23.00 price objective for the company. Evercore ISI started coverage on shares of Stealth BioTherapeutics in a report on Tuesday, March 12th. They set an “outperform” rating and a $35.00 price objective for the company. Finally, BMO Capital Markets started coverage on shares of Stealth BioTherapeutics in a report on Tuesday, March 12th. They set an “outperform” rating and a $29.00 price objective for the company. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $23.80.
An institutional investor recently bought a new position in Stealth BioTherapeutics stock. Dean Capital Investments Management LLC acquired a new stake in shares of Stealth BioTherapeutics Corp (NASDAQ:MITO) in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 50,420 shares of the company’s stock, valued at approximately $646,000. Dean Capital Investments Management LLC owned approximately 0.18% of Stealth BioTherapeutics at the end of the most recent reporting period.
Stealth BioTherapeutics Company Profile
Stealth BioTherapeutics Corp, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies for diseases involving mitochondrial dysfunction. Its lead product candidate, Elamipretide, has the potential to treat rare genetic and common age-related mitochondrial diseases.
See Also: What are the FAANG Stocks?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Stealth BioTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stealth BioTherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.